Plasma secretory phospholipase A2 as an early marker for late-onset sepsis in preterm infants—a pilot study

Julie Hibbert, Nicola J. Armstrong, Caitlyn Granland, Sherrianne Ng, Karen Simmer, Peter Richmond, David Burgner, Tobias Strunk, Andrew Currie

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Preterm infants are particularly susceptible to bacterial late-onset sepsis (LOS). Diagnosis by blood culture and inflammatory markers have sub-optimal sensitivity and specificity and prolonged reporting times. There is an urgent need for more rapid, accurate adjunctive diagnostics in LOS to improve management and minimise antibiotic exposure. We measured the diagnostic performance of secretory phospholipase A2 type IIA (sPLA2-IIA) in very preterm infants (<30 weeks gestational age) with suspected LOS. Plasma sPLA2-IIA levels were elevated in infants with LOS (n = 28) compared to those without LOS (n = 21; median 30,970 vs. 2534 pg/ml, p < 0.0001). The mean area under the curve was 0.884 (95% CI: 0.771, 0.977) with a sensitivity of 0.907 (95% CI: 0.667, 1.00) and specificity of 0.804 (95% CI: 0.600, 1.00). The positive and negative predictive values were 0.833 (95% CI: 0.664, 0.927) and 0.842 (95% CI: 0.624, 0.945), respectively. This pilot study suggests that sPLA2-IIA may have clinical utility for the early diagnosis of LOS in very preterm infants, potentially informing clinical management and antibiotic stewardship.

Original languageEnglish
Pages (from-to)3011-3013
Number of pages3
JournalActa Paediatrica, International Journal of Paediatrics
Volume110
Issue number11
DOIs
Publication statusPublished - Nov 2021

Fingerprint

Dive into the research topics of 'Plasma secretory phospholipase A2 as an early marker for late-onset sepsis in preterm infants—a pilot study'. Together they form a unique fingerprint.

Cite this